#BoehringerIngelheim #BIL #Jascayd #pulmonaryfibrosis #idiopathicpulmonaryfibrosis #IPF #progressivepulmonaryfibrosis #MarketAccess #IPFtherapy #MHRA #PDE4Binhibitor #FIBRONEERIPFtrial #FIBRONEERILDtrial #lungfunction #NHS #pulmonaryfibrosispatients #ActionforPulmonaryFibrosis
zurl.co/O6bD4
zurl.co/O6bD4
UK first in Europe to clear Boehringer's IPF drug Jascayd
Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.
pharmaphorum.com
July 10, 2026 at 8:49 AM